Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02052973
Other study ID # 10726612.8.0000.5149
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received January 29, 2014
Last updated July 20, 2015
Start date September 2014
Est. completion date July 2015

Study information

Verified date July 2015
Source Federal University of Minas Gerais
Contact n/a
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in Research
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the effectiveness of a varnish containing 15% of green propolis on Streptococcus mutans in saliva and biofilm. Will be invited to join the study: children 8-10 years old, free of caries, without orthodontic appliances and without having undergone antibiotic therapy until three weeks before the start of the study. Saliva will be collected before, immediately after, 24 hours and 30 days after application of the varnish. The collection of biofilm will be performed before, after, 24 hours and 30 days after application of the varnish. Data will be collected and compared between periods.


Description:

Antimicrobials are substances used in dentistry as an efficient way of caries prevention. Substances such as chlorhexidine are the most known and most applied for this purpose and, as a varnish, increased its anticariogenic potential. The antimicrobial effects of natural substances are being studied for exhibiting antimicrobial properties similar to those of chlorhexidine, but less toxic in some cases. Several studies with propolis has proven its efficacy against several microorganisms of the oral cavity, specially Streptococcus mutans. A pharmaceutical formulation containing brazilian green propolis was developed based on the chitosan polymer that is biocompatible and biodegradable. In a previous study, we observed in vitro antimicrobial properties of the varnish against Streptococcus mutans. This work aims to study the preliminary evidence of the efficacy of the propolis dental varnish in reducing Streptococcus mutans in saliva and in the biofilm control through a phase II study involving patients with 8-10 years. After 30 days, the results will be compared and statistically analyzed at a level of significance of 5 % .


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date July 2015
Est. primary completion date January 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 8 Years to 10 Years
Eligibility Inclusion Criteria:

- children 8-10 years old

- good general health condition

- not making use of mouthwashes or medications (especially antibiotics), until three weeks prior to the beginning of the experiment.

Exclusion Criteria:

- Patients in medical treatment or who used drugs (especially antibiotics), in the three previous weeks and patients with active caries lesions.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Propolis varnish
Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Federal University of Minas Gerais Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Outcome

Type Measure Description Time frame Safety issue
Primary Streptococcus mutans in saliva and in tooth biofilm 30 days Yes
Secondary Caries incidence reduction Up to 24 months Yes
See also
  Status Clinical Trial Phase
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT01193920 - Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age Phase 1/Phase 2
Terminated NCT00261742 - Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis Phase 4
Completed NCT00169481 - A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine Phase 2
Completed NCT02270944 - Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine Phase 2
Completed NCT03055728 - Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
Withdrawn NCT00598429 - Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure Phase 2
Completed NCT01030731 - Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease Phase 1
Completed NCT04100772 - Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above Phase 1
Completed NCT01118143 - Oral Health Literacy Tailored Communication N/A
Completed NCT01026740 - Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers Phase 1
Withdrawn NCT00330642 - Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study N/A
Completed NCT00299663 - Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract N/A
Completed NCT00646958 - Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections Phase 2
Completed NCT01026558 - A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients Phase 1
Completed NCT00514527 - A Study for Patients With Complicated Skin and Skin Structure Infections Phase 2
Completed NCT01026636 - A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age Phase 1
Completed NCT01156740 - Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings N/A
Completed NCT04841369 - Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) Phase 3